tetano
Editor, Senior Moderator
Cancers (Basel)
. 2020 Nov 25;12(12):E3513.
doi: 10.3390/cancers12123513.
Impact of SARS-CoV-2 Infection on Patients with Cancer: Retrospective and Transversal Studies in Spanish Population
Javier Garde-Noguera[SUP] 1 [/SUP], M Leonor Fern?ndez-Murga[SUP] 1 [/SUP], Vicent Giner-Bosch[SUP] 2 [/SUP], Victoria Dominguez-M?rquez[SUP] 3 [/SUP], Jos? Garc?a S?nchez[SUP] 1 [/SUP], Juan Jos? Soler-Catalu?a[SUP] 4 [/SUP], Franscica L?pez Chuli?[SUP] 5 [/SUP], Beatriz Honrubia[SUP] 1 [/SUP], Nuria Piera[SUP] 1 [/SUP], Antonio Llombart-Cussac[SUP] 1 6 7 8 [/SUP]
Affiliations
Abstract
Background: Studies of patients with cancer affected by coronavirus disease 2019 (COVID-19) are needed to assess the impact of the disease in this sensitive population, and the influence of different cancer treatments on the COVID-19 infection and seroconversion.
Material and methods: We performed a retrospective analysis of all patients hospitalized with RT-PCR positive for COVID-19 in our region to assess the prevalence of cancer patients and describe their characteristics and evolution (Cohort 1). Concurrently, a transversal study was carried out in patients on active systemic cancer treatment for symptomatology and seroprevalence (IgG/IgM by ELISA-method) against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Cohort 2).
Results: A total of 215 patients (Cohort 1) were admitted to hospital with a confirmed COVID-19 infection between February 28 and April 30, 2020, and 17 died (7.9%). A medical record of cancer was noted in 43 cases (20%), 6 of them required Intensive care unit ICU attention (14%), and 7 died (16%). There were thirty-six patients (83%) who tested IgG/IgM positive for SARS-CoV-2. Patients on immunosuppressive therapies presented a lower ratio of seroconversion (40% vs. 8%; p = 0.02). In Cohort 2, 166 patients were included in a symptoms-survey and tested for SARS-CoV-2. Any type of potential COVID-19-related symptom was referred up to 67.4% of patients (85.9% vs. 48.2% vs. 73.9%, for patients on chemotherapy, immunotherapy and targeted therapies respectively, p < 0.05). The seroprevalence ratio was 1.8% for the whole cohort with no significant differences by patient or treatment characteristics.
Conclusion: Patients with cancer present higher risks for hospital needs for COVID-19 infection. The lack of SARS-CoV-2 seroconversion may be a concern for patients on immunosuppressive therapies. Patients receiving systematic therapies relayed a high rate of potentially COVID-19-related symptoms, particularly those receiving chemotherapy. However, the seroconversion rate remains low and in the range of general population.
Keywords: COVID-19; SARS-CoV-2; cancer; chemotherapy; immunotherapy; seroprevalence; targeted therapy.
. 2020 Nov 25;12(12):E3513.
doi: 10.3390/cancers12123513.
Impact of SARS-CoV-2 Infection on Patients with Cancer: Retrospective and Transversal Studies in Spanish Population
Javier Garde-Noguera[SUP] 1 [/SUP], M Leonor Fern?ndez-Murga[SUP] 1 [/SUP], Vicent Giner-Bosch[SUP] 2 [/SUP], Victoria Dominguez-M?rquez[SUP] 3 [/SUP], Jos? Garc?a S?nchez[SUP] 1 [/SUP], Juan Jos? Soler-Catalu?a[SUP] 4 [/SUP], Franscica L?pez Chuli?[SUP] 5 [/SUP], Beatriz Honrubia[SUP] 1 [/SUP], Nuria Piera[SUP] 1 [/SUP], Antonio Llombart-Cussac[SUP] 1 6 7 8 [/SUP]
Affiliations
- PMID: 33255856
- DOI: 10.3390/cancers12123513
Abstract
Background: Studies of patients with cancer affected by coronavirus disease 2019 (COVID-19) are needed to assess the impact of the disease in this sensitive population, and the influence of different cancer treatments on the COVID-19 infection and seroconversion.
Material and methods: We performed a retrospective analysis of all patients hospitalized with RT-PCR positive for COVID-19 in our region to assess the prevalence of cancer patients and describe their characteristics and evolution (Cohort 1). Concurrently, a transversal study was carried out in patients on active systemic cancer treatment for symptomatology and seroprevalence (IgG/IgM by ELISA-method) against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Cohort 2).
Results: A total of 215 patients (Cohort 1) were admitted to hospital with a confirmed COVID-19 infection between February 28 and April 30, 2020, and 17 died (7.9%). A medical record of cancer was noted in 43 cases (20%), 6 of them required Intensive care unit ICU attention (14%), and 7 died (16%). There were thirty-six patients (83%) who tested IgG/IgM positive for SARS-CoV-2. Patients on immunosuppressive therapies presented a lower ratio of seroconversion (40% vs. 8%; p = 0.02). In Cohort 2, 166 patients were included in a symptoms-survey and tested for SARS-CoV-2. Any type of potential COVID-19-related symptom was referred up to 67.4% of patients (85.9% vs. 48.2% vs. 73.9%, for patients on chemotherapy, immunotherapy and targeted therapies respectively, p < 0.05). The seroprevalence ratio was 1.8% for the whole cohort with no significant differences by patient or treatment characteristics.
Conclusion: Patients with cancer present higher risks for hospital needs for COVID-19 infection. The lack of SARS-CoV-2 seroconversion may be a concern for patients on immunosuppressive therapies. Patients receiving systematic therapies relayed a high rate of potentially COVID-19-related symptoms, particularly those receiving chemotherapy. However, the seroconversion rate remains low and in the range of general population.
Keywords: COVID-19; SARS-CoV-2; cancer; chemotherapy; immunotherapy; seroprevalence; targeted therapy.